Trending NewsTrending NewsNASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis $554.73 -4.37 (-0.78%) Closing price 04:00 PM EasternExtended Trading$550.29 -4.44 (-0.80%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About United Therapeutics Stock (NASDAQ:UTHR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get United Therapeutics alerts:Sign Up Key Stats Today's Range$551.77▼$563.1250-Day Range$472.21▼$608.4952-Week Range$455.63▼$614.23Volume367,682 shsAverage Volume524,465 shsMarket Capitalization$23.63 billionP/E Ratio20.93Dividend YieldN/APrice Target$676.40Consensus RatingModerate Buy Company Overview United Therapeutics is a biotechnology company that develops and commercializes treatments for serious diseases, with a primary focus on pulmonary arterial hypertension (PAH). Its therapies include treprostinil products delivered by injection, inhalation, or oral tablet, marketed under brands including Remodulin, Tyvaso, and Orenitram. The company also markets Unituxin, a treatment for high-risk neuroblastoma. Founded in 1996 by Martine Rothblatt, United Therapeutics is also pursuing technologies intended to address the shortage of transplantable organs. Its research includes organ manufacturing approaches such as 3D bioprinting and the development of organs for transplantation. Headquartered in Silver Spring, Maryland, the company serves patients in the United States and in selected international markets. Rothblatt remains the company’s chair and chief executive officer.AI Generated. May Contain Errors. Read More United Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks93rd Percentile Overall ScoreUTHR MarketRank™: 4.64660408614 of 5 starsUnited Therapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 17th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on no strong buy ratings, 12 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialUnited Therapeutics has a consensus price target of $676.40, representing about 21.9% upside from its current price of $554.73.Amount of Analyst CoverageUnited Therapeutics has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about United Therapeutics' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth27.79% Earnings GrowthEarnings for United Therapeutics are expected to grow by 27.79% in the coming year, from $25.08 to $32.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 22.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.30.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 22.18, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.47.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 3.91. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 3.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.72% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 3.45, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in United Therapeutics has recently decreased by 25.23%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.39 News SentimentUnited Therapeutics has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 21 news articles for United Therapeutics this week, compared to 11 articles on an average week.Search InterestOnly 12 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -8% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $230,189,518.00 in company stock.Percentage Held by Insiders8.60% of the stock of United Therapeutics is held by insiders.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about United Therapeutics' insider trading history. Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UTHR Stock News HeadlinesUnited Therapeutics Corporation Announces First Clinical Xenotransplant in Extend Study of Uthymokidney in Patients with End-Stage Renal Disease2 hours ago | marketscreener.comMUnited Therapeutics (UTHR) Stock May Be Below Fair Value Following EXTEND Trial Transplant News2 hours ago | finance.yahoo.comWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and the shift is already underway. The dollar has lost 88% of its purchasing power since it was untethered from gold, and Fortune calls the current change the biggest shift in the world's relationship with the dollar in a generation. Stansberry says a similar reset is planned to be unveiled in Miami as soon as this December. Watch Porter Stansberry's full broadcast to see which companies could be affected.November 20 at 1:00 AM | Porter & Company (Ad)United Therapeutics (UTHR) Stock Dropped, What Is Behind The Fresh Attention?2 hours ago | finance.yahoo.comUnited Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 5,410 SharesNovember 20 at 6:52 AM | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) Director Sells $701,800.00 in StockNovember 11, 2026 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $5,362,845.00 in StockNovember 10, 2026 | insidertrades.comUnited Therapeutics (NASDAQ:UTHR) CEO Sells $5,700,855.00 in StockNovember 3, 2026 | insidertrades.comSee More Headlines UTHR Stock Analysis - Frequently Asked Questions How have UTHR shares performed this year? United Therapeutics' stock was trading at $487.25 at the beginning of 2026. Since then, UTHR shares have increased by 13.8% and is now trading at $554.73. How were United Therapeutics' earnings last quarter? United Therapeutics Corporation (NASDAQ:UTHR) announced its earnings results on Wednesday, November, 4th. The biotechnology company reported $5.71 EPS for the quarter, missing analysts' consensus estimates of $6.01 by $0.30. The business's revenue was up 4.1% compared to the same quarter last year. Read the conference call transcript. Is United Therapeutics buying back stock? United Therapeutics' board initiated a stock buyback program on Thursday, October 22nd 2026, which authorizes the company to repurchase $2 billion in shares, according to EventVestor. This means that the company could reacquire up to 8.3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its stock is undervalued. Who are United Therapeutics' major shareholders? Top institutional shareholders of United Therapeutics include State Street Corp (4.58%), First Trust Advisors LP (0.82%), Soleus Capital Management L.P. (0.61%) and Pictet Asset Management Holding SA (0.55%). Insiders that own company stock include Martine A Rothblatt, Paul A Mahon, Richard Giltner, James Edgemond, Ray Kurzweil, Tommy G Thompson, Nilda Mesa, Judy D Olian, Christopher Causey, Christopher Patusky, Raymond Dwek, Jan Malcolm, Michael Benkowitz and Louis W Sullivan. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that United Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Broadcom (AVGO), Bristol Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Micron Technology (MU). Company Calendar Last Earnings11/04/2026Today11/20/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 UTHR's financial health is in the Green zone, according to TradeSmith. UTHR has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,400Year Founded1996Price Target and Rating Average Price Target for United Therapeutics$676.40 High Price Target$850.00 Low Price Target$368.00 Potential Upside/Downside+21.9%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage16 Analysts Profitability EPS (Trailing Twelve Months)$26.50 Trailing P/E Ratio22.18 Forward P/E Ratio17.31 P/E Growth3.91Net Income$1.33 billion Net Margins38.61% Pretax Margin47.30% Return on Equity19.18% Return on Assets17.07% Debt Debt-to-Equity RatioN/A Current Ratio4.61 Quick Ratio4.29 Sales & Book Value Annual Sales$3.18 billion Price / Sales7.42 Cash Flow$31.13 per share Price / Cash Flow17.82 Book Value$147.36 per share Price / Book3.76Miscellaneous Outstanding Shares42,590,000Free Float38,926,000Market Cap$23.63 billion OptionableOptionable Beta0.49 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:UTHR) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share United Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.